Overview

This trial has been completed.

Condition cystinosis
Treatment rp103 q12h
Phase phase 3
Sponsor Horizon Pharma USA, Inc.
Start date December 2012
End date December 2016
Trial size 17 participants
Trial identifier NCT01744782, RP103-08

Summary

This is a long-term, open-label study of the safety, tolerability and effectiveness of RP103 in cystinosis patients who are naïve to any form of cysteamine treatment. Subjects will receive RP103 treatment for at least 12 months. US subjects will transition to the commercially approved drug PROCYSBI®. In Brazil, after at least 12 months of study participation and upon approval by the Brazilian regulatory authorities, subjects will be eligible to transition to a post study drug supply program, and continue to receive the drug at no personal cost.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
Arm
(Experimental)
From Day 1 and throughout the duration of participation, subjects will take RP103 (Cysteamine Bitartrate Delayed-release Capsules) every 12 hours, supplied in 75mg and 25mg capsules.
rp103 q12h (Cysteamine Delayed-release Capsules)

Primary Outcomes

Measure
White Blood Cell (WBC) Cystine Levels
time frame: 12 months minimum

Secondary Outcomes

Measure
Long-Term Safety and Tolerability
time frame: 12 months minimum
Pharmacokinetic Assessment (Cmax, maximum concentration)
time frame: 12 months minimum
Pharmacokinetic Assessment (Tmax, time to maximum concentration)
time frame: 12 months minimum
Pharmacokinetic Assessment (AUC, area under the curve)
time frame: 12 months minimum

Eligibility Criteria

All participants up to 6 years old.

Inclusion Criteria: - Male or female with a documented diagnosis of cystinosis - No clinically significant change in liver function tests, i.e. 1.5 times ULN for ALT and AST, and/or 1.5 times ULN for total bilirubin, within 6 months prior to Screening - No clinically significant change in renal function, i.e. estimated GFR within 6 months prior to Screening - Must have an estimated GFR > 20 mL/minute/1.73m2 (using the equation from Schwartz 2009 J Am Soc Nephrol 20:629-647) - Female subjects who are sexually active and of childbearing potential, i.e. not surgically sterile (tubal ligation, bilateral oopherectomy, or hysterectomy) or at least 2 years naturally postmenopausal must agree to use an acceptable form of contraception from Screening through completion of the study. Acceptable forms of contraception for this study include hormonal contraceptives (oral, implant, transdermal patch, or injection) at a stable dose for at least 3 months prior to Screening, barrier (spermicidal condom or diaphragm with spermicide), IUD, or a partner who has been vasectomized for at least 6 months. [NB: Childbearing potential is defined as a female who has reached menarche.] - Subject or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study - Has not taken any form of cysteamine bitartrate in the past Exclusion Criteria: - Current history of the following conditions or any other health issues that make it, in the opinion of the investigator, unsafe for study participation: - Inflammatory bowel disease if currently active, or prior resection of the small intestine - Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias, or poorly controlled hypertension) within 90 days prior to Screening - Active bleeding disorder within 90 days prior to Screening - History of malignant disease within 2 years prior to Screening - Hemoglobin level of < 10 g/dL at Screening or, in the opinion of the investigator, a hemoglobin level that would make it unsafe for study participation - Known hypersensitivity to penicillamine - Female subjects who are nursing, planning a pregnancy, or are known or suspected to be pregnant - Subjects who, in the opinion of the investigator, are not able or willing to comply with study requirements - Has received a kidney transplant or is currently on dialysis - Is 6 years of age or older at the time of the Screening visit

Additional Information

Official title An Open-Label, Safety and Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naïve Patients With Cystinosis
Description The purpose of this study is to gather information about the safety and effectiveness (how well it works to treat cystinosis) of a new drug called RP103. In cystinosis, the body builds up cystine. When taken regularly, the active ingredient of an older, already approved drug called Cystagon® (cysteamine bitartrate) reduces cystine in the body. RP103 has the same active ingredient as Cystagon® and is designed to reduce cystine in a similar way that Cystagon® does. RP103 is also different from Cystagon®: Instead of the cysteamine bitartrate being absorbed from the stomach, RP103 is designed to be absorbed from the small intestine. This may make the effects of the drug last longer, so that it can be taken twice a day instead of four times a day like Cystagon®. To decide if RP103 is effective, the study will look at two types of blood tests. One test is pharmacodynamics (PD), which measures the amount of white blood cell (WBC) cystine after taking study drug. WBC cystine is a laboratory test used to find out if cysteamine bitartrate is reducing cystine levels in the body. The second test is pharmacokinetics (PK), which measures the amount of cysteamine in the blood after taking the drug.
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Horizon Pharma USA, Inc..